Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

5-Alpha Reductase and Anabolic Effects of Testosterone

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00475501
First received: April 16, 2007
Last updated: June 27, 2014
Last verified: June 2014

April 16, 2007
June 27, 2014
January 2007
March 2012   (final data collection date for primary outcome measure)
1 Repetition Maximum (1-RM) Strength Testing [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
1-RM strength testing for 5 exercises will be performed using dynamic resistance exercise machines. Testing will be performed before treatment (baseline), at 3, 6, 9 and 12 months after treatment.
  • 1-RM strength testing for 5 exercises will be performed using dynamic resistance exercise machines. Testing will be performed before treatment (baseline), at 3, 6, 9 and 12 months after treatment and at 3 months after completion of treatment.
  • Grip strength in the dominant arm will be measured by using a Jamar dynamometer. Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up.
  • Functional reach is measured as the furthest a subject can reach forward without taking a step. Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up.
  • Dual x-ray absorptiometry (DXA): We will assess bone mineral density (BMD) and body composition using a fan-bean densitometer (Lunar Prodigy, GE Medical Systems).
  • Geriatric Depression Scale (GDS): This 30-item, yes/no questionnaire will be administered at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up.
  • Rey Osterrieth Complex Figure (ROCF) test is a widely used standardized neuropsychological test for assessing visuospatial constructional functions, visuographic memory, and some aspects of planning.
  • Trail-Making Test, Parts A&B (Trails A&B): is a standardized test of cognitive function which specifically assesses working memory, visual processing, visual spatial skills, selective and divided attention, and psychomotor coordination.
  • Benton Judgment of Line Orientation Test is a standardized test with 30 items that is specific for visual spatial cognition. Tests will be administered at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up.
  • Blood analysis will be performed as follows: CBC (complete blood count), CMP (complete metabolic profile), Hgb A1C, LH, lipids, total testosterone, bioavailable testosterone and IGF-I.
Complete list of historical versions of study NCT00475501 on ClinicalTrials.gov Archive Site
  • Grip Strength kg [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
    Grip strength in the dominant arm will be measured by using a dynamometer. Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment.
  • Lumbar Spine L2-L4 Bone Mineral Density [ Time Frame: baseline, 12 months ] [ Designated as safety issue: No ]
    Dual x-ray absorptiometry (DXA): We will assess bone mineral density (BMD) and body composition using a fan-bean densitometer (Lunar Prodigy, General Electric Medical Systems).
  • Geriatric Depression Scale [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]

    Geriatric Depression Scale (GDS): This 15-item, yes/no questionnaire will be administered at baseline, after 3, 6, 9 and 12 months of treatment.

    The minimum score is 0 = no depressive symptoms The maximum score is 15 = a very high level of depressive symptoms

  • 30 Minute Recall Portion of Rey Osterrieth Complex Figure (ROCF) Test [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]

    Rey Osterrieth Complex Figure (ROCF) test is a widely used standardized neuropsychological test for assessing visuospatial constructional functions, visuographic memory, and some aspects of planning.

    The drawing is scored by a blinded neuropsychologist on a scale of 0 to 30 with 30 representing a perfect drawing.

  • Trail-Making Test, Part A [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
    Trail-Making Test, Part A: is a standardized test of cognitive function which specifically assesses working memory, visual processing, visual spatial skills, selective and divided attention, and psychomotor coordination. the test is scored as seconds required to successful completion of the task with a lower score representing better performance. The mean score on test is 30.75 second with a standard deviation of 16.27.
  • Benton Judgment of Line Orientation Test [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: Yes ]

    Benton Judgment of Line Orientation Test is a standardized test with 30 items that is specific for visual spatial cognition. Tests will be administered at baseline, after 3, 6, 9 and 12 months of treatment.

    The minimum score is 0, indicating low visual spatial cognition. The maximum score is 30, indicating high visual spatial cognition

  • Hematocrit [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
    Hematocrit was assessed as a part of routine blood analysis at the indicated time points.
  • Dietary Protein Intake [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: Yes ]
    Dietary protein intake will be assessed using a 3-day food log and subjects will be counseled to increase protein intake if needed using the guide "Healthy Ways to Eat More Protein".
  • Transrectal Ultrasound Sizing of Prostate [ Time Frame: baseline, 6 month, 12 months ] [ Designated as safety issue: No ]
    Transrectal ultrasound sizing of prostate will be performed using the B&K Diagnostic System 3535, with 7 mega hertz transrectal probe at baseline and after 6 and 12 months of treatment.
  • Life Satisfaction [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
    Life Satisfaction: is a written test of psychological well-being that will be performed at baseline, after 3, 6, 9 and 12 months of treatment. This is a 20-point scale, with a possible range of scores from 0 to 20. A higher score represents greater life satisfaction.
  • Dietary protein intake will be assessed using a 3-day food log and subjects will be counseled to increase protein intake if needed using the guide “Healthy Ways to Eat More Protein”.
  • Transrectal ultrasound sizing of prostate will be performed using the B&K Diagnostic System 3535, with 7MHz transrectal probe at baseline and after 6 and 12 months of treatment.
  • Life Satisfaction: is a written test of psychological well-being that will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up.
Not Provided
Not Provided
 
5-Alpha Reductase and Anabolic Effects of Testosterone
5-Alpha Reductase and Anabolic Effects of Testosterone

The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.

Approximately 40% of older male veterans have a low serum testosterone concentration. The latter is associated with diminished muscle strength and bone mineral density, depressed mood, low pain tolerance, frailty, and increased mortality. Replacement doses of testosterone have been administered to hypogonadal men for the purpose of reversing deficits in muscle and bone. Although testosterone is clearly important for maintaining muscle and bone in men, there are problems associated with T replacement. First, testosterone causes a number of undesired effects, including fluid retention, gynecomastia, worsening of sleep apnea, polycythemia, prostate enlargement and acceleration of early-stage prostate cancer. The anabolic effects obtained to date from testosterone replacement have been relatively modest, especially in older men. Our hypothesis is that combined treatment with a higher-than-replacement dose of testosterone and a 5- reductase inhibitor will produce substantial anabolic effects, while preventing testosterone-induced prostate enlargement and possibly other adverse effects.

We plan to investigate the efficacy and safety of combined treatment with testosterone and finasteride in older hypogonadal male veterans by conducting a 12-month randomized, placebo-controlled trial. We will administer a higher-than-replacement dose of testosterone plus the 5- reductase inhibitor finasteride to a group of hypogonadal, but otherwise healthy older men. We will determine whether this treatment is a safe and effective means to increase muscle mass and strength. Men aged 60 to 80, with circulating total testosterone 300 ng/dL or bioavailable testosterone 70 ng/dL, will be treated with 125 mg testosterone enanthate/week 5 mg finasteride/day for 1 year. We will assess the effects on body composition, 1- repetition maximum (1-RM) strength, grip strength, functional reach, bone mineral density, mood, cognition, hematopoiesis and prostate volume. We have chosen a moderately high dose of testosterone that may cause some adverse effects. We predict that finasteride will not block the anabolic effects of testosterone, but will block any prostate enlargement or symptoms and possibly other adverse effects as well.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Male Hypogonadism
  • Muscle Atrophy
  • Benign Prostate Hypertrophy
  • Sarcopenia
  • Drug: Testosterone Enanthate
    125 mg, i.m. injection, once/week, for 52 weeks
    Other Name: Delatestryl
  • Drug: Finasteride
    5 mg, oral, once/day, for 52 weeks
    Other Name: Proscar
  • Experimental: Arm 1
    testosterone enanthate
    Intervention: Drug: Testosterone Enanthate
  • Experimental: Arm 2
    finasteride
    Intervention: Drug: Finasteride
  • Experimental: Arm 3
    testosterone enanthate + finasteride
    Interventions:
    • Drug: Testosterone Enanthate
    • Drug: Finasteride
  • Placebo Comparator: Arm 4
    placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
October 2014
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 60 years males
  • Primary care at the Malcolm Randall VA Medical Center in Gainesville, Florida.
  • Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusion criteria will be randomized to receive either testosterone or placebo.

Exclusion Criteria:

  • Subjects with cognitive impairment will be identified by the Mini-Cog test and excluded. The Mini-Cog has high sensitivity and specificity for cognitive impairment, and is not affected by level of education.
  • We will also exclude subjects with receptive aphasia, or a contraindication to testosterone replacement (i.e., history of or active prostate or breast cancer, severe benign prostatic hyperplasia as assessed by elevated American Urologic Association Symptom Index (AUASI) score > 25), congestive heart failure (Class 3 or 4), sleep apnea syndrome, polycythemia (Hct > 55%), or prostate specific antigen (PSA) > 2.6 ng/mL) will be excluded.
  • Obese subjects (BMI > 35) will also be excluded.
  • Subjects currently receiving testosterone supplementation or subjects who have an allergy to testosterone will also be excluded.
  • Subjects previously receiving testosterone replacement therapy must be off such medication for at least four weeks.
Male
60 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00475501
ENDA-014-05F, VA Merit Award
No
Department of Veterans Affairs
Department of Veterans Affairs
  • Endo Pharmaceuticals
  • Merck Sharp & Dohme Corp.
Principal Investigator: Stephen Borst, PhD North Florida/South Georgia Veterans Health System
Department of Veterans Affairs
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP